Almirall SA (Almirall) is a pharmaceutical company primarily focused on skin health. It engages in the purchase, manufacture, storage, marketing, and mediation in the sale of pharmaceutical specialties and products. The company also deals with cosmetics, chemicals, biotechnological, and diagnostic products for various uses, including human and veterinary. Almirall's business portfolio includes a wide range of medical solutions aimed at treating skin diseases such as psoriasis, actinic keratosis, atopic dermatitis, acne, vitiligo, onychomycosis, skin cancer, and hidradenitis suppurativa. The company also focuses on rare skin diseases. Almirall's product portfolio is complemented by therapeutic divisions in central nervous, cardiovascular, gastrointestinal, and musculoskeletal systems.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Almirall's R&D arm focuses on transforming the lives of patients through innovative research and development in medical dermatology. The company has established a multi-target partnership with Evotec, focusing on combining Evotec’s AI/ML-based EVOiR&D platform with Almirall’s expertise in medical dermatology. Almirall has also acquired global rights from Ichnos Science to develop and market ISB 880, an IL-1RAP antagonist for autoimmune diseases, and from Simcere for SIM0278, an IL-2 mutant fusion protein for autoimmune diseases. Additionally, Almirall has formed alliances with Etherna for mRNA-based therapies, Absci for AI-engineered therapies, Novo Nordisk for NN-8828, and Eloxx Pharmaceuticals for ZKN-013. The company’s pipeline includes late-stage products such as Tirbanibulin for actinic keratosis and Tildrakizumab for psoriatic arthritis, among others. In FY2025, the company incurred R&D expenses of EUR96 million, which accounted for 8.7% of the company’s total revenue and grew 21.5% YoY. Almirall's R&D activities are managed through its global innovation ecosystem, with a focus on life-science innovation and business development. The company has opened new offices in Shanghai to enhance collaboration, scientific exchange, and strategic partnerships, complementing its core R&D center in Sant Feliu de Llobregat, Barcelona. Almirall has R&D centers in Sant Feliu de Llobregat, Barcelona, and Shanghai. The company has formed major technology alliances with Evotec, Ichnos Science, Simcere, Etherna, Absci, Novo Nordisk, and Eloxx Pharmaceuticals. The pipeline includes 14 late-stage products, focusing on various dermatological conditions.